Literature DB >> 12584540

Myeloid leukemia in Prader-Willi syndrome.

H Dele Davies1, Geraline L Leusink, Athena McConnell, Marc Deyell, Suzanne B Cassidy, Gordon H Fick, Max J Coppes.   

Abstract

OBJECTIVE: To evaluate the frequency of cancers recorded by the Surveillance, Epidemiology, and End Results (SEER) Program in persons with Prader-Willi syndrome (PWS)
METHODS: A survey was mailed in 1994 to 1852 registrants of the PWS Association (USA) inquiring about a diagnosis of any type of benign tumor or cancer (malignant tumor or leukemia). The risk of developing cancer was then estimated by comparing the observed number of cancers in the PWS population during 1975 to 1994 to the expected number in the general US population using data from the 1971-1994 SEER Cancer Statistics Review.
RESULTS: Of the 1852 persons, 1160 (63%) responded, or 75% (1160/1552) of those who received the survey. The total number of observed cancer cases in the PWS study population was 8 versus 4.80 expected in the general US population (P =.1610). Three cases of myeloid leukemia were observed versus 0.075 leukemias expected (P =.0001).
CONCLUSIONS: There appears to be an increased risk of myeloid leukemias, but not other cancers, among persons with PWS.

Entities:  

Mesh:

Year:  2003        PMID: 12584540     DOI: 10.1067/mpd.2003.81

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  14 in total

Review 1.  Oncogenic potential of yin yang 1 mediated through control of imprinted genes.

Authors:  Michelle M Thiaville; Joomyeong Kim
Journal:  Crit Rev Oncog       Date:  2011

Review 2.  The p53 tumor suppressor protein regulates hematopoietic stem cell fate.

Authors:  Takashi Asai; Yan Liu; Narae Bae; Stephen D Nimer
Journal:  J Cell Physiol       Date:  2011-09       Impact factor: 6.384

Review 3.  Epigenetic aberrations in human pluripotent stem cells.

Authors:  Shiran Bar; Nissim Benvenisty
Journal:  EMBO J       Date:  2019-05-14       Impact factor: 11.598

Review 4.  The p53 tumor suppressor protein is a critical regulator of hematopoietic stem cell behavior.

Authors:  Yan Liu; Shannon E Elf; Takashi Asai; Yasuhiko Miyata; Yuhui Liu; Goro Sashida; Gang Huang; Silvana Di Giandomenico; Andrew Koff; Stephen D Nimer
Journal:  Cell Cycle       Date:  2009-10-01       Impact factor: 4.534

5.  Very high birth weight of offspring is associated with an increased risk of leukemia in their mothers: results of a population-based cohort study.

Authors:  Ora Paltiel; Rebecca Yanetz; Ronit Calderon-Margalit; Orly Manor; Nir Sharon; Susan Harlap; Yehiel Friedlander
Journal:  Leuk Res       Date:  2008-05-15       Impact factor: 3.156

6.  Genes involved in differentiation, stem cell renewal, and tumorigenesis are modulated in telomerase-immortalized human urothelial cells.

Authors:  Emma J Chapman; Gavin Kelly; Margaret A Knowles
Journal:  Mol Cancer Res       Date:  2008-07       Impact factor: 5.852

7.  Putative tumour suppressor gene necdin is hypermethylated and mutated in human cancer.

Authors:  L E De Faveri; C D Hurst; F M Platt; C F Taylor; J-A Roulson; M Sanchez-Carbayo; M A Knowles; E J Chapman
Journal:  Br J Cancer       Date:  2013-04-02       Impact factor: 7.640

8.  Causes of death in Prader-Willi syndrome: lessons from 11 years' experience of a national reference center.

Authors:  Dibia Liz Pacoricona Alfaro; Perrine Lemoine; Virginie Ehlinger; Catherine Molinas; Gwénaëlle Diene; Marion Valette; Graziella Pinto; Muriel Coupaye; Christine Poitou-Bernert; Denise Thuilleaux; Catherine Arnaud; Maithé Tauber
Journal:  Orphanet J Rare Dis       Date:  2019-11-04       Impact factor: 4.123

9.  Necdin modulates leukemia-initiating cell quiescence and chemotherapy response.

Authors:  Chonghua Yao; Michihiro Kobayashi; Sisi Chen; Sarah C Nabinger; Rui Gao; Stephen Z Liu; Takashi Asai; Yan Liu
Journal:  Oncotarget       Date:  2017-09-18

10.  Incomplete methylation of a germ cell tumor (Seminoma) in a Prader-Willi male.

Authors:  Talia Eldar-Geva; Varda Gross-Tsur; Harry J Hirsch; Gheona Altarescu; Reeval Segal; Sharon Zeligson; Eliahu Golomb; Silvina Epsztejn-Litman; Rachel Eiges
Journal:  Mol Genet Genomic Med       Date:  2018-07-12       Impact factor: 2.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.